We and others have confirmed that this CD133+/CD44+ cell population makes up a subset of prostate cancer cells that are self renewing, differentiate into heterogeneous tumors, and are highly tumorigenic in immunodeficient mice [5], [7], [8], [9], [10], [11], [12]. Here, CD44 is linked to prostate carcinoma.